Biological Skin Substitutes Market - By Type (Human Donor Tissue-derived, Acellular Animal-derived, Tissue-Engineered, Biosynthetic), Application (Acute & Chronic Wound), End-use (Hospital, ASC) – Global Forecast, 2023-2032

Biological Skin Substitutes Market Size

Biological Skin Substitutes Market size was valued at USD 287 million in 2022 and is estimated to account for USD 640 million by 2032. Biological skin substitutes, also known as skin grafts, are medical products used to replace or regenerate damaged or lost skin tissue. Chronic wounds, such as venous leg ulcers, diabetic ulcers and pressure ulcers, are becoming more common.
 

For instance, according to the NIH data, there are around 9.1 to 26.1 million new cases of diabetic foot ulcers worldwide each year. These wounds often require advanced wound care solutions such as biological skin substitutes, to promote healing. Therefore, as the prevalence of chronic wounds continues to rise, the demand for biological skin substitutes will also increase.
 

Furthermore, burn injuries and trauma cases, including accidents and surgeries, often result in complex wounds. Biological skin substitutes offer a valuable solution in such cases by providing a scaffold for tissue regeneration and wound healing. For instance, the National Library of Medicine (NLM) in India reports 6-7 million annual burn cases, while the American Association for the Surgery of Trauma states that the U.S. sees over 150,000 fatalities and 3 million non-fatal injuries annually. Therefore, with the increasing incidence of burn injuries and trauma cases, there is a growing need for effective wound care biologics such as biological skin substitutes.
 

COVID-19 Impact

The COVID-19 pandemic had a detrimental impact on the biological skin substitutes market, primarily due to disruptions in supply chains, reduced demand for non-urgent medical procedures, resource reallocation, financial strain on healthcare system, d, and market uncertainty. These factors collectively led to decreased adoption of biological skin substitutes and deferred treatments for chronic wounds and burns. Therefore, the pandemic significantly hindered the growth and operational dynamics of the market for biological skin substitutes.  
 

Biological Skin Substitutes Market Trends

Advances in regenerative medicine which is estimated to reach USD 328.9 billion by 2032 have led to the development of more sophisticated biological skin substitutes. These products are designed to closely mimic the properties of natural skin, offering improved wound healing outcomes. For instance, AVITA Medical, Inc.'s RECELL System has been launched for the treatment of full-thickness skin defects. This system harvests a patient's skin and creates a regenerative cell suspension, referred to as Spray-On Skin Cells, which promotes healing and re-pigmentation within the wound bed. Thus, patients and healthcare providers are increasingly turning to this type of advanced solutions, further fuelling market growth.
 

• The healthcare industry has seen a surge in the establishment and utilization of wound care facilities, including wound care centers and clinics. These facilities are equipped with advanced technologies and expertise to manage and treat complex wounds effectively.


• Therefore, as the awareness and availability of specialized wound care facilities continue to grow, the demand for biological skin substitutes as a part of comprehensive wound care will also rise.
   

Biological Skin Substitutes Market Analysis

The market by type is categorized into human donor tissue-derived products, acellular animal-derived products, tissue-engineered skin products and biosynthetic skin products. The human donor tissue-derived products segment garnered USD 188 million revenue size in the year 2022. The dominance of the segment can be attributed to their exceptional biological compatibility, proven safety record, and established efficacy.
 

• These products closely mimic natural human skin, ensuring seamless integration and effective tissue regeneration. Furthermore, their reliability and trustworthiness have been demonstrated through extensive clinical studies and real-world applications, reinforcing their position in the market.
   
• With regulatory approvals and a well-structured supply chain, they are readily available and accessible to healthcare providers and patients. Moreover, higher patient preference for these products further bolsters their market dominance.
   

Based on application, the biological skin substitutes market is segmented into acute wounds, chronic wounds, and others. The acute wounds segment for over 59% business share in the year 2022. High segment growth is attributed to their higher incidence, immediate treatment requirements, and positive clinical outcomes.
 

• These wounds, including surgical incisions, traumatic injuries, and emergency cases, demand swift and effective wound care solutions, making biological skin substitutes the preferred choice.
• Additionally, these products excel in promoting rapid healing, reducing scarring, and supporting surgical procedures, especially in emergency and orthopedic contexts.
   

Therefore, the widespread utilization and adoption of these products in addressing acute wounds contribute significantly towards the growth of the segment.
 

The biological skin substitutes market by end-use is categorized into hospitals, ambulatory surgical centers, specialty clinics and others. The hospitals segment garnered USD 143 million revenue size in the year 2022.
 

• Hospital’s clinical expertise, state-of-the-art facilities, and skilled healthcare workforce make them the primary choice for patients with complex wounds, burns, and surgical needs.
   
• Furthermore, hospitals also see a high volume of patients, creating substantial demand for biological skin substitutes in various wound care applications. Thus, these products are vital in surgical procedures, emergency care, and wound management, further reinforcing hospitals' dominance in this segment.
   

U.S. biological skin substitutes market accounted for USD 109 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline.
 

• The U.S. has solidified its dominant position in the market, primarily attributed to the annual increase in burn injuries. The American Burn Association reports around 486,000 yearly burn injuries, with 40,000 of these cases requiring hospitalization.
   
• Furthermore, U.S. advanced healthcare infrastructure, leadership in innovative medical practices, high surgical volumes, and accessibility to advanced products contribute to its central role in the market.
   

Biological Skin Substitutes Market Share

The biological skin substitutes industry is consolidated, with major players such as Mylan N.V., Misonix, Inc., and others dominating the market. These companies are focused on continuous product innovation to secure a significant market share. For instance, Misonix is known for its Theraskin product, which is a biosynthetic skin substitute that combines synthetic materials with biological components to promote wound healing.
 

Some of the eminent market participants operating in the biological skin substitutes industry include:

• Organogenesis Inc
• Smith & Nephew plc
• MiMedx Group, Inc.
• Misonix, Inc. (Bioventus)
• Avita Medical
• Stratatech Corporation (Mallinckrodt Pharmaceuticals)
• BioTissue
• Aroa Biosurgery
• ProgenaCare
• Mimedx Group (MiMedx Group, Inc.)
• Tissue Regenix
• Stryker
• Vericel Corporation
• Integra LifeSciences
   

Biological Skin Substitutes Industry News:

• In January 2023, MiMedx Group, Inc. partnered with Gunze Medical, to introduce EPIFIX, a PURION processed placental tissue allograft, to the Japanese market. EPIFIX acts as a protective barrier for wound healing and offers a human biocompatible extracellular matrix with over 300 regulatory proteins. The collaboration aimed to expand the company's geographical reach, grow its customer base, and boost revenue.
   
• In October 2021, Bioventus Inc., a global leader in innovations for active healing, acquired Misonix, Inc. This strategic move was anticipated to lead to increased innovation, research, and geographical expansion, ultimately offering more effective wound care solutions to patients and healthcare providers.
   

Biological skin substitutes market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type, 2018-2032 (USD Million)

• Human donor tissue-derived products
• Acellular animal-derived products
• Tissue-engineered skin products
• Biosynthetic skin products

By Application, 2018-2032 (USD Million)

• Acute wounds
• Chronic wounds
• Other applications

By End-use, 2018-2032 (USD Million)

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa